TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04424199

Intervention type: BEHAVIORAL
Intervention: Rightward Attentional Shift (R-PA)
Description: Patients will perform a session of 90 pointing movements toward a visual target presented on the right, the left or at the center of the visual field. This pointing task will be performed with prismatic googles inducing a rightward attentional shift.

Intervention type: BEHAVIORAL
Intervention: Rightward Attentional Shift (R-PA)
Description: Patients will perform a session of 90 pointing movements toward a visual target presented on the right, the left or at the center of the visual field. This pointing task will be performed with prismatic googles inducing a rightward attentional shift.

Intervention type: BEHAVIORAL
Intervention: Rightward Attentional Shift (R-PA)
Description: Patients will perform a session of 90 pointing movements toward a visual target presented on the right, the left or at the center of the visual field. This pointing task will be performed with prismatic googles inducing a rightward attentional shift.

Intervention type: BEHAVIORAL
Intervention: Leftward Attentional Shift (L-PA)
Description: Patients will perform a session of 90 pointing movements toward a visual target presented on the right, the left or at the center of the visual field. This pointing task will be performed with prismatic googles inducing a leftward attentional shift.

Intervention type: BEHAVIORAL
Intervention: Leftward Attentional Shift (L-PA)
Description: Patients will perform a session of 90 pointing movements toward a visual target presented on the right, the left or at the center of the visual field. This pointing task will be performed with prismatic googles inducing a leftward attentional shift.

Intervention type: BEHAVIORAL
Intervention: Leftward Attentional Shift (L-PA)
Description: Patients will perform a session of 90 pointing movements toward a visual target presented on the right, the left or at the center of the visual field. This pointing task will be performed with prismatic googles inducing a leftward attentional shift.
Study: NCT01800279

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy Protocol
Description: Kinesitherapy~* Patient: supine position on the stretcher with a loop of 6 cm in the cervical area.~* Tongue in the palate for all applied exercises.~* Repetitions of each exercise: 8. Cervical traction. Cranium fore flexion 15 °. Open-close mouth dental contactless (10mm). Opening movement with a small resistor (one finger on chin).~Flexion of the head, without actually lifting, resisting in the front. Occipital extension. Cranium fore flexion 15 °. Cervical traction.~Myofascial Therapy. Induction suboccipital. Compression - decompression of the TMJ (Temporomandibular Joint). Horizontal Induction TMJ. Deep fascia induction in the temporal region. Deep Induction of the masseter fascia. Deep Induction of the external pterygoid. Induction of intraoral pterygoid.
Study: NCT01101204

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin 1000mg, simvastatin 10mg and fenofibrate 100mg
Description: Patient will take three pill consisting of metformin 1000mg, simvastatin 10mg and fenofibrate 100mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin 1000mg, simvastatin 10mg and fenofibrate 100mg
Description: Patient will take three pill consisting of metformin 1000mg, simvastatin 10mg and fenofibrate 100mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin 1000mg, simvastatin 10mg and fenofibrate 100mg
Description: Patient will take three pill consisting of metformin 1000mg, simvastatin 10mg and fenofibrate 100mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin 1000mg, simvastatin 10mg and fenofibrate 100mg
Description: Patient will take three pill consisting of metformin 1000mg, simvastatin 10mg and fenofibrate 100mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin 1000mg, simvastatin 10mg and fenofibrate 100mg
Description: Patient will take three pill consisting of metformin 1000mg, simvastatin 10mg and fenofibrate 100mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin 1000mg, simvastatin 10mg and fenofibrate 100mg
Description: Patient will take three pill consisting of metformin 1000mg, simvastatin 10mg and fenofibrate 100mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin 1000mg, simvastatin 10mg and fenofibrate 100mg
Description: Patient will take three pill consisting of metformin 1000mg, simvastatin 10mg and fenofibrate 100mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin 1000mg, simvastatin 10mg and fenofibrate 100mg
Description: Patient will take three pill consisting of metformin 1000mg, simvastatin 10mg and fenofibrate 100mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin 1000mg, simvastatin 10mg and fenofibrate 100mg
Description: Patient will take three pill consisting of metformin 1000mg, simvastatin 10mg and fenofibrate 100mg.
Study: NCT03118388

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Enterprise Intervention
Description: The SEI model was implemented in four stages: 1) Vocational skill acquisition (4 months); 2) Small business skill acquisition (4 months); 3) SEI formation and product distribution (12 months); and 4) Clinical/case-management services, (ongoing for 20 months).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IPS
Description: To implement the IPS at the host agency, one employment specialist, two case managers, and two clinicians were assigned the 22 available IPS cases among them at baseline. Over the 20 months, all IPS participants met individually with the employment specialist, one case manager, and one clinician at least weekly. Regarding job development in the community, the IPS employment specialist also spent about 40% of each week out in the community building relationships with new and existing employers.
Study: NCT01176617

Intervention type: DEVICE
Group type: OTHER
Intervention: Reveal XT implantable loop recorder
Description: All study participants will receive the Reveal XT implantable loop recorder immediately after completion of the ablation procedure.
Study: NCT02668926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine, d-amphetamine, Placebo
Description: Elvanse (Lisdexamfetamine): 100mg p.o, single dose; d-Amphetamine: 40.3mg p.o, single dose; Placebo: Capsules containing mannitol looking identical to lisdexamphetamine and d-Amphetamine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: d-amphetamine, Placebo, Lisdexamfetamine
Description: Elvanse (Lisdexamfetamine): 100mg p.o, single dose; d-Amphetamine: 40.3mg p.o, single dose; Placebo: Capsules containing mannitol looking identical to lisdexamphetamine and d-Amphetamine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo, Lisdexamfetamine, d-amphetamine
Description: Elvanse (Lisdexamfetamine): 100mg p.o, single dose; d-Amphetamine: 40.3mg p.o, single dose; Placebo: Capsules containing mannitol looking identical to lisdexamphetamine and d-Amphetamine.
Study: NCT00771745

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thymoglobulin
Description: Preloading Induction with Thymoglobulin® X 4 doses given day -4, day -2, day 0, and day 2 at 1.5 mg/kg/dose + corticosteroid taper + tacrolimus + MMF

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thymoglobulin
Description: Preloading Induction with Thymoglobulin® X 3 doses given day -4 (1.5mg/kg), day -2 (1.5mg/kg), and day 0 (3mg/kg) + corticosteroid taper + tacrolimus + MMF
Study: NCT00836771

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Infant Formula

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Infant Formula

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Infant Formula

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Infant Formula

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Infant Formula
Study: NCT01642446

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Precise hepatectomy
Description: Precise hepatectomy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Combined intervention (chemoembolization/ablation)
Description: transcatheter hepatic arterial chemoembolization and/or ablation
Study: NCT03376464

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Xeomin Cosmetic
Description: Xeomin Cosmetic is the purest commercially available botulinum toxin type A available to date. It has been approved by Health Canada since 2012 for the temporary improvement in the appearance of moderate to severe glabellar lines.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Xeomin Cosmetic
Description: Xeomin Cosmetic is the purest commercially available botulinum toxin type A available to date. It has been approved by Health Canada since 2012 for the temporary improvement in the appearance of moderate to severe glabellar lines.
Study: NCT00746525

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Surface functional electrical stimulation (FES)
Description: FES is a technique that electrically stimulates a muscle in a comfortable manner in order to contract the muscle. It uses an electrode placed on the surface of the skin. This study will use BCI, FES, and motor learning interventions to address upper extremity motor deficits following stroke.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor learning
Description: Motor learning is an exercise that uses movements needed for everyday tasks such as picking up a glass or opening a book. This study will use BCI, FES, and motor learning interventions to address upper extremity motor deficits following stroke.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brain computer interface (BCI) training
Description: BCI training uses signals produced by the brain to help individuals with stroke move their weak arm. This study will use BCI, FES and motor learning interventions to address upper extremity motor deficits following stroke.
Study: NCT00444925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fesoterodine fumarate
Description: 4 mg once daily (OD) for 1 week followed by a forced dose-escalation to 8 mg once daily (OD) for 11 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: once daily (OD)for 12 weeks
Study: NCT00993070

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capsaicin
Description: 0.025% topical capsaicin applied 4 times per day for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: vehicle gel, applied 4 times per day for 8 weeks
Study: NCT01032837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Description: Oseltamivir capsules for participants ≥ 13 years.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Description: Oseltamivir capsules for participants ≥ 13 years.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Description: Oseltamivir capsules for participants ≥ 13 years.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Description: Oseltamivir capsules for participants ≥ 13 years.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Description: Pediatric suspension for participants aged ≤ 12 years.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Description: Pediatric suspension for participants aged ≤ 12 years.
Study: NCT01800279

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Deontology Therapy
Description: For the realization of the splint, the following protocol will be developed at the Faculty of Dentistry of Granada (Spain):~* Impression of the maxilla with chromatic alginate Phase plus (Zhermack ©, Rovigo, Italy).~* Emptying working models in plaster-stone type IV Elite Rock (Zhermack ©, Rovigo, Italy).~* Deprogramming occlusal splints were made of polyester plates with terephthalic acid of 3 mm thick Clear 120 model (Dentaflux ©, Ripoll, Madrid). We used a molding machine of thermoplastic vacuum plate The Machine Dentaflux ©, Ripoll, Madrid.
Study: NCT02854553

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transversus abdominis plane block
Description: ultra sound guides Transversus abdominis plane block
Study: NCT01032837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Description: Pediatric suspension for participants aged ≤ 12 years.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Description: Pediatric suspension for participants aged ≤ 12 years.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo provided as capsules and as a suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo provided as capsules and as a suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo provided as capsules and as a suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo provided as capsules and as a suspension.
Study: NCT02746796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-4538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-4538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-4538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxaliplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegafur- Gimeracil-Oteracil potassium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegafur- Gimeracil-Oteracil potassium

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tegafur- Gimeracil-Oteracil potassium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Capecitabine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02271568

Intervention type: PROCEDURE
Intervention: Bariatric surgery
Description: Laparoscopic or Robot R-Y gastric bypass

Intervention type: OTHER
Intervention: Intensive medical therapy
Description: intensive medical therapy according to published guidelines by ADA and EASD
Study: NCT04375371

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bariatric surgery
Description: Obese patients who haveundergone bariatric surgery as part of routine clinical management within the indication of this intervention.
Study: NCT05723978

Intervention type: PROCEDURE
Intervention: Selective extended dissection of pancreaticoduodenectomy
Description: An optimized procedure of pancreaticoduodenectomy which is based on the extra-pancreatic nerve plexus (PLX) potentially invaded by tumor.
Study: NCT02554500

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote Ischemic Preconditioning (by Blood Pressure Cuff)
Description: Remote Ischemik Preconditioning is performed using a Blood Pressure Cuff with a pressure slightly above patients' blood pressure on the upper arm.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote Ischemic Preconditioning (by Blood Pressure Cuff)
Description: Remote Ischemik Preconditioning is performed using a Blood Pressure Cuff with a pressure slightly above patients' blood pressure on the upper arm.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote Ischemic Preconditioning (by Blood Pressure Cuff)
Description: Remote Ischemik Preconditioning is performed using a Blood Pressure Cuff with a pressure slightly above patients' blood pressure on the upper arm.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote Ischemic Preconditioning (by Blood Pressure Cuff)
Description: Remote Ischemik Preconditioning is performed using a Blood Pressure Cuff with a pressure slightly above patients' blood pressure on the upper arm.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote Ischemic Preconditioning (by Blood Pressure Cuff)
Description: Remote Ischemik Preconditioning is performed using a Blood Pressure Cuff with a pressure slightly above patients' blood pressure on the upper arm.
Study: NCT01523262

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: preconditioning
Description: peripheral preconditioning induced by brief, intermittent constriction of blood supply to an arm

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Normal surgery, with sham intervention without inflating arm cuff
Study: NCT03953196

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Imvanex
Description: Imvanex 0.5 milliliter (mL) suspension for injection will be administered as single subcutaneous (SC) injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Shingrix
Description: Shingrix 0.5 mL suspension will be administered as single intramuscular (IM) injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LPS
Description: LPS 1.0 nanogram per kilogram (ng/kg) endotoxin suspension will be administered as single IV injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Candin
Description: Candin 0.1 mL solution for injection will be administered as one intradermal injection.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skin Biopsy
Description: 3 punch biopsies will be performed and lower abdomen tissue biopsy specimens will be collected on Day 1.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline Control
Description: Saline control solution for injection will be administered as one intradermal injection.
Study: NCT02900196

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1 - Fermented dairy drink
Description: 1 - Fresh fermented dairy drink containing yoghurt ferments and probiotic strains consumed as follows: one bottle (100g) BID for 28 consecutive days (Day 0 to day 28)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 2 - Acidified dairy drink
Description: 2 - Acidified dairy drink without ferments consumed as follows: one bottle (100g) BID for 28 consecutive days (Day 0 to day 28)
Study: NCT03591991

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin
Description: After randomization,the treatment started 30 minutes before PCI with a dose of 10 mg empagliflozin . After admission, patients were treated with 10 mg empagliflozin once daily for 3 mouths.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: After randomization,the treatment started 30 minutes before PCI with a dose of 10 mg placebo . After admission, patients were treated with 10 mg placebo once daily for 3 mouths.
Study: NCT03355716

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: bupivacaine
Description: Bupivacaine 25 ml (0.25%)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine
Description: Bupivacaine 25 ml (0.25%)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine
Description: Bupivacaine 25 ml (0.25%)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine
Description: Bupivacaine 25 ml (0.25%)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: morphine
Description: Morphine (3.0 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fentanyl
Description: fentanyl (30.0 Mc)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine:
Description: ketamine (0.5 mg/kg).
Study: NCT03155568

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: sciatic nerve block
Description: sciatic nerve block at popliteal fossa

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: sciatic nerve block
Description: sciatic nerve block at popliteal fossa

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ankle block
Description: block of major nerves supplying the foot at the level of the ankle

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ankle block
Description: block of major nerves supplying the foot at the level of the ankle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: blocking the lower limb nerve supply at the level of the popliteal fossa and ankle using the local anesthetic bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: blocking the lower limb nerve supply at the level of the popliteal fossa and ankle using the local anesthetic bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: blocking the lower limb nerve supply at the level of the popliteal fossa and ankle using the local anesthetic bupivacaine
Study: NCT02276001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Study: NCT02023606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPN-810M
Study: NCT04152278

Intervention type: DIAGNOSTIC_TEST
Intervention: cervicovaginal culture and qPCR for chlamydial trachomatis and wadallia chondrophila
Description: three cervicovaginal swabs were obtained: one was used for a smear test of vaginal fluid pH evaluation and direct microscopy, the second swabs, cultured for aerobic and anaerobic bacteria and yeasts, the third was eluted in 2-sucrose-phosphate (2SP) based transport medium. Placental samples from the study group were cultured for aerobic and anaerobic bacteria. Placenta sample and 2SP medium were stored at -80°C until their analysis by real time PCR (qPCR)

Intervention type: DIAGNOSTIC_TEST
Intervention: cervicovaginal culture and qPCR for chlamydial trachomatis and wadallia chondrophila
Description: three cervicovaginal swabs were obtained: one was used for a smear test of vaginal fluid pH evaluation and direct microscopy, the second swabs, cultured for aerobic and anaerobic bacteria and yeasts, the third was eluted in 2-sucrose-phosphate (2SP) based transport medium. Placental samples from the study group were cultured for aerobic and anaerobic bacteria. Placenta sample and 2SP medium were stored at -80°C until their analysis by real time PCR (qPCR)